Advertisement
CRSP vs HUMA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and HUMA is a Buy.
CRSP's RSI Oscillator descending into oversold zone
The RSI Oscillator for CRSP moved into overbought territory on November 12, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 81 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 40 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for CRSP moved below the 200-day moving average on November 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CRSP entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.772) is normal, around the industry mean (3.498). P/E Ratio (-10.631) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. CRSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
HUMA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for HUMA turned positive on October 21, 2026. Looking at past instances where HUMA's MACD turned positive, the stock continued to rise in 36 of 40 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on HUMA as a result. In 78 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
HUMA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +0.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUMA advanced for three days, in 194 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 148 of 170 cases where HUMA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
HUMA broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. HUMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.983) is normal, around the industry mean (3.498). P/E Ratio (-0.862) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (52.083) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CRSP | HUMA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 42 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 23 Undervalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 100 | |
PRICE GROWTH RATING 1..100 | 71 | 43 | |
P/E GROWTH RATING 1..100 | 53 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 25 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRSP's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for HUMA (72) in the null industry. This means that CRSP’s stock grew somewhat faster than HUMA’s over the last 12 months.
CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HUMA (100) in the null industry. This means that CRSP’s stock grew similarly to HUMA’s over the last 12 months.
CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as HUMA (100) in the null industry. This means that CRSP’s stock grew similarly to HUMA’s over the last 12 months.
HUMA's Price Growth Rating (43) in the null industry is in the same range as CRSP (71) in the Biotechnology industry. This means that HUMA’s stock grew similarly to CRSP’s over the last 12 months.
HUMA's P/E Growth Rating (14) in the null industry is somewhat better than the same rating for CRSP (53) in the Biotechnology industry. This means that HUMA’s stock grew somewhat faster than CRSP’s over the last 12 months.
| CRSP | HUMA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 87% |
| Advances ODDS (%) | 16 days ago 82% | 1 day ago 81% |
| Declines ODDS (%) | 4 days ago 81% | 12 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRSP’s FA Score shows that 1 FA rating(s) are green while HUMA’s FA Score has 1 green FA rating(s).
- CRSP’s FA Score: 1 green, 4 red.
- HUMA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRSP’s TA Score shows that 4 TA indicator(s) are bullish while HUMA’s TA Score has 5 bullish TA indicator(s).
- CRSP’s TA Score: 4 bullish, 6 bearish.
- HUMA’s TA Score: 5 bullish, 4 bearish.
Price Growth
CRSP (@Biotechnology) experienced а -12.23% price change this week, while HUMA (@Biotechnology) price change was +50.54% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.04%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -16.99%.
Reported Earning Dates
CRSP is expected to report earnings on Feb 16, 2027.
HUMA is expected to report earnings on Mar 26, 2027.
Industries' Descriptions
@Biotechnology (+2.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
HUMA and
Correlation & Price change
A.I.dvisor indicates that over the last year, HUMA has been loosely correlated with PROK. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if HUMA jumps, then PROK could also see price increases.
| Ticker / NAME | Correlation To HUMA | 1D Price Change % | ||
|---|---|---|---|---|
| HUMA | 100% | +0.63% | ||
| PROK - HUMA | 36% Loosely correlated | +1.77% | ||
| ABCL - HUMA | 35% Loosely correlated | -2.76% | ||
| CRSP - HUMA | 35% Loosely correlated | -6.84% | ||
| EDIT - HUMA | 34% Loosely correlated | -10.08% | ||
| SANA - HUMA | 34% Loosely correlated | -12.23% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| APRZ | 40.00 | 0.28 | +0.71% |
| TrueShares Structured Outcome (April) ETF (APRZ) | |||
| FB | 44.62 | -0.02 | -0.04% |
| ProShares S&P 500 Dynamic Buffer ETF (FB) | |||
| FTRI | 16.74 | -0.19 | -1.11% |
| First Trust Indxx Global Natural Resources Income ETF (FTRI) | |||
| MXI | 108.08 | -1.52 | -1.39% |
| iShares Global Materials ETF (MXI) | |||
| PFFA | 18.08 | -0.26 | -1.42% |
| Virtus InfraCap U.S. Preferred Stock ETF (PFFA) | |||